Business
IN8bio to Present Positive Preclinical Data on Novel Gamma-Delta CAR Platform at AACR Annual Meeting 2023
INB-300, a gamma-delta T cell based chimeric antigen receptor (CAR) platform, demonstrated the ability to target malignant cells while preserving healthy
About this update from In8bio, Inc.
[{"type":"text","content":"INB-300, a gamma-delta T cell based chimeric antigen receptor (CAR) platform, demonstrated the ability to target malignant cells while preserving healthy tissue. Data supports the potential for this next-generation CAR-T technology in previously “undruggable” solid- and liquid-tumor targets. NEW YORK, March 16, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, has announced that preclinical data for its gamma-delta CAR-T technology, INB-300, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023. The event will be held in Orlando, Florida, from April 14-19. IN8bio's non-signaling CAR (nsCAR) platform is based on the natural innate immune recognition of gamma-delta T cells. By using a CAR that lacks a CD3z signaling domain, IN8bio believes it has created a technology that enables these cells to differentiate between tumor and healthy tissue, even when both express the CAR-targeted antigen. IN8bio is not seeking to advance this construct into the clinic but the data to be presented includes a proof-of-concept study against the validated target of CD19. INB-300, a CD19 targeting nsCAR construct (ns19CAR), demonstrated the ability to distinguish between leukemic and healthy cells, killing 80% of the leukemia cells and only 5% of healthy B cells, both of which express CD19. Updated data, along with planned next steps for this nsCAR platform, will be presented at the AACR Annual Meeting. \"We are thrilled to present promising preclinical data from our next-generation CAR platform, which shows the potential of INB-300 to differentiate between cancerous and healthy tissue,\" said Lawrence Lamb, Ph.D., co-founder and Chief Scientific Officer of IN8bio. \"Our goal is to improve upon existing technologies with a targeted and potentially less toxic approach for patients who require more innovative therapies. We are encouraged by these results and look forward to further evaluating nsCAR programs in additional promising targets such as CD33 for acute myeloid leukemia (AML).\" AACR Presentation Details Title: A non-signaling CAR for gamma-delta (γδ) T cells to preserve healthy tissues Abstract Presentation Number: 1777 Session Title: CAR T-cell Therapy 1 Session Date and Time: Monday, April 1...